Torben Skovsgaard

5.6k total citations
85 papers, 4.6k citations indexed

About

Torben Skovsgaard is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Torben Skovsgaard has authored 85 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 42 papers in Molecular Biology and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Torben Skovsgaard's work include Drug Transport and Resistance Mechanisms (28 papers), Cancer therapeutics and mechanisms (22 papers) and Cancer Treatment and Pharmacology (20 papers). Torben Skovsgaard is often cited by papers focused on Drug Transport and Resistance Mechanisms (28 papers), Cancer therapeutics and mechanisms (22 papers) and Cancer Treatment and Pharmacology (20 papers). Torben Skovsgaard collaborates with scholars based in Denmark, Israel and Italy. Torben Skovsgaard's co-authors include Dorte Nielsen, Benny Vittrup Jensen, Julie Gehl, Lluis M. Mir, Thomas Litman, Stig Lønberg Nielsen, Wilfred D. Stein, P Dombernowsky, Thomas Zeuthen and Maxwell Sehested and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Torben Skovsgaard

85 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Torben Skovsgaard Denmark 35 2.8k 1.8k 750 512 499 85 4.6k
Shigeru Tsukagoshi Japan 32 3.0k 1.1× 2.7k 1.6× 203 0.3× 236 0.5× 196 0.4× 144 5.4k
Bert L. Lum United States 38 2.4k 0.8× 1.8k 1.0× 212 0.3× 818 1.6× 119 0.2× 83 4.7k
K. Mross Germany 37 3.1k 1.1× 2.1k 1.2× 289 0.4× 1.0k 2.0× 90 0.2× 148 5.2k
Sharon Marsh United States 43 3.0k 1.1× 2.9k 1.7× 302 0.4× 648 1.3× 72 0.1× 109 6.7k
M. Marty France 41 3.5k 1.3× 1.4k 0.8× 267 0.4× 1.0k 2.0× 1.1k 2.2× 128 6.3k
E Frei United States 42 2.2k 0.8× 1.8k 1.0× 372 0.5× 1.2k 2.3× 98 0.2× 104 6.1k
Sewa S. Legha United States 46 4.0k 1.4× 1.7k 1.0× 850 1.1× 1.1k 2.1× 52 0.1× 138 6.4k
Massimo Zucchetti Italy 40 1.9k 0.7× 1.8k 1.0× 140 0.2× 579 1.1× 95 0.2× 170 4.8k
Youcef M. Rustum United States 51 3.7k 1.3× 3.5k 2.0× 184 0.2× 1.3k 2.6× 199 0.4× 246 8.2k
Alan V. Boddy United Kingdom 41 2.2k 0.8× 2.4k 1.4× 183 0.2× 670 1.3× 75 0.2× 188 5.9k

Countries citing papers authored by Torben Skovsgaard

Since Specialization
Citations

This map shows the geographic impact of Torben Skovsgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torben Skovsgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torben Skovsgaard more than expected).

Fields of papers citing papers by Torben Skovsgaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torben Skovsgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torben Skovsgaard. The network helps show where Torben Skovsgaard may publish in the future.

Co-authorship network of co-authors of Torben Skovsgaard

This figure shows the co-authorship network connecting the top 25 collaborators of Torben Skovsgaard. A scholar is included among the top collaborators of Torben Skovsgaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torben Skovsgaard. Torben Skovsgaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ryberg, Marianne, Dorte Nielsen, Giuliana Cortese, et al.. (2008). New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients. JNCI Journal of the National Cancer Institute. 100(15). 1058–1067. 125 indexed citations
2.
Litman, Thomas, Torben Skovsgaard, & Wilfred D. Stein. (2003). Pumping of Drugs by P-Glycoprotein: A Two-Step Process?. Journal of Pharmacology and Experimental Therapeutics. 307(3). 846–853. 52 indexed citations
3.
Litman, Thomas, Alastair Hansen, Zhirong Zhan, et al.. (2002). Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1565(1). 6–16. 103 indexed citations
4.
Punt, Cornelis J.A., H.J. Keizer, J. Douma, et al.. (2002). Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Annals of Oncology. 13(1). 81–86. 21 indexed citations
5.
Glimelius, Bengt, Raija Ristamäki, Michael Kjær, et al.. (2002). Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Annals of Oncology. 13(12). 1868–1873. 31 indexed citations
6.
Nielsen, Dorte, Christian Maare, Jens Eriksen, et al.. (2000). Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide. Biochemical Pharmacology. 60(3). 353–361. 6 indexed citations
7.
Nielsen, Dorte, Jens Eriksen, Christian Maare, et al.. (2000). Characterisation of Non-P-Glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone. Biochemical Pharmacology. 60(3). 363–370. 9 indexed citations
8.
Lehne, Gustav, Erkki Elonen, M. Baekelandt, Torben Skovsgaard, & Curt Peterson. (1998). Challenging Drug Resistance in Cancer Therapy: Review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997. Acta Oncologica. 37(5). 431–439. 18 indexed citations
9.
Ryberg, M., Dorte Nielsen, Torben Skovsgaard, et al.. (1998). Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.. Journal of Clinical Oncology. 16(11). 3502–3508. 223 indexed citations
10.
Litman, Thomas, Dorte Nielsen, Torben Skovsgaard, Thomas Zeuthen, & Wilfred D. Stein. (1997). ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1361(2). 147–158. 49 indexed citations
11.
Nielsen, Dorte, Vibeke Schiøler, Torben Skovsgaard, et al.. (1993). A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Annals of Oncology. 4(10). 861–869. 22 indexed citations
12.
Sessa, Cristiana, F. Calabresi, F. Cavalli, et al.. (1991). Phase II studies of 4’-iodo-4’-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Annals of Oncology. 2(10). 727–731. 6 indexed citations
13.
Friche, Ellen, Peter Buhl Jensen, Henrik Roed, Torben Skovsgaard, & N. I. Nissen. (1990). In vitro circumvention of anthracycline-resistance in ehrlich ascites tumour by anthracycline analogues. Biochemical Pharmacology. 39(11). 1721–1726. 24 indexed citations
14.
Jensen, Peter Buhl, et al.. (1990). Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemotherapy and Pharmacology. 27(3). 194–198. 13 indexed citations
15.
Vindeløv, Lars L., et al.. (1989). In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). British Journal of Cancer. 60(6). 838–844. 31 indexed citations
16.
Friche, Ellen, Torben Skovsgaard, & N. I. Nissen. (1989). Anthracycline Resistance. Acta Oncologica. 28(6). 877–881. 11 indexed citations
17.
Sehested, Maxwell, Torben Skovsgaard, & Henrik Roed. (1988). The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Biochemical Pharmacology. 37(17). 3305–3310. 40 indexed citations
18.
Sehested, Maxwell, et al.. (1987). Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. British Journal of Cancer. 56(6). 747–751. 73 indexed citations
19.
Skovsgaard, Torben, et al.. (1985). Treatment of small cell lung cancer with 6-mercaptopurine: a phase II study.. PubMed. 69(5). 555–555. 3 indexed citations
20.
Skovsgaard, Torben. (1978). Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(6). 1785–91. 248 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shigeru Tsukagoshi Breakdown of academic impact, for papers by Bert L. Lum Breakdown of academic impact, for papers by K. Mross Breakdown of academic impact, for papers by Sharon Marsh Breakdown of academic impact, for papers by M. Marty Breakdown of academic impact, for papers by E Frei Breakdown of academic impact, for papers by Sewa S. Legha Breakdown of academic impact, for papers by Massimo Zucchetti Breakdown of academic impact, for papers by Youcef M. Rustum Breakdown of academic impact, for papers by Alan V. Boddy
Rankless by CCL
2026